In a pre-clinical model of CAR-T therapy, the addition of ibrutinib significantly reduced serum cytokines associated with CRS including IFNγ, IL-6, TNFα, IL-2, and GM-CSF [20]. Here, IL6 is linked to congenital rubella syndrome.